AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

Ki vehet részt

• Male or female age ≥ 18 years
• Confirmed diagnosis of DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient
• Must have at least one living ≥ 18 years FDR
• Able to provide informed consent
• Male or female age ≥ 18 years who are first-degree relatives of patients with DCM
• Proband has provided informed consent
• FDR able to provide informed consent
• Access to a smartphone or digital tablet with cellular data or Wi-Fi access

Ki nem vehet részt

• Proband has previously informed FDR to undergo cardiac screening
• Previously informed about cardiac screening or has completed cardiac screening by TTE
• Congenital structural heart disease
• Severe and untreated or untreatable hypertension
• Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload
• Ischemic cause of reduced LVEF; evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease; history of acute coronary syndromes (STEMI, NSTEMI or unstable angina) revascularization or ≥75% stenosis of either left main or LAD or ≥75% stenosis of 2 major epicardial vessels on angiogram
• Any secondary cause of reduced LVEF such as peripartum cardiomyopathy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
• Previously diagnosed with reduced LVEF
• DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination
• Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy
• (CPC Participants only) Home address outside of traveling range
• (CPC Participants only) Home address outside of traveling range